Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12100152rdf:typepubmed:Citationlld:pubmed
pubmed-article:12100152lifeskim:mentionsumls-concept:C0003402lld:lifeskim
pubmed-article:12100152lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:12100152lifeskim:mentionsumls-concept:C0027540lld:lifeskim
pubmed-article:12100152lifeskim:mentionsumls-concept:C0376448lld:lifeskim
pubmed-article:12100152lifeskim:mentionsumls-concept:C0000894lld:lifeskim
pubmed-article:12100152lifeskim:mentionsumls-concept:C0439836lld:lifeskim
pubmed-article:12100152pubmed:issue1lld:pubmed
pubmed-article:12100152pubmed:dateCreated2002-7-8lld:pubmed
pubmed-article:12100152pubmed:abstractTextWe treated rapidly growing Jurkat cells with 40 nmol/l of doxorubicin for 72 h. After 36 h, the G2-arrested cells became larger and some of them started endoreplication. Nuclear staining with Hoechst 33342 combined with propidium iodide (PI) exclusion revealed that about 90% of the cells were necrotic at 72 h, although apoptotic cells accounted for only 8%. Incubation with 40 nmol/l of aclarubicin or cytosine beta-d-arabinofuranoside for 60 h induced necrosis both in Jurkat and ml-1 cells. Pre-necrotic Jurkat cells incubated with 40 nmol/l of doxorubicin had much higher intracellular reactive oxygen species (ROS) levels than pre-apoptotic ones. Addition of Tempol or Desferal accelerated doxorubicin-induced necrosis and partially converted it into apoptosis. Both antioxidants reduced surviving colony numbers of prenecrotic Jurkat cells. n-acetyl-l-cysteine had little effect on the apoptotic conversion but profoundly accelerated necrosis. Because an apoptosis-resistant Jurkat subclone was also refractory to doxorubicin-induced necrosis, apoptosis and necrosis might share some common pathways. Low-dose doxorubicin increased micronuclei-positive cell percentages and also suppressed high-dose doxorubicin-induced apoptosis in Jurkat and ml-1 cells. Some of the prenecrotic cells, therefore, might survive and obtain genomic instability. Antioxidants may be useful to suppress, at least to some extent, this vicious consequence.lld:pubmed
pubmed-article:12100152pubmed:languageenglld:pubmed
pubmed-article:12100152pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:citationSubsetIMlld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12100152pubmed:statusMEDLINElld:pubmed
pubmed-article:12100152pubmed:monthJullld:pubmed
pubmed-article:12100152pubmed:issn0007-1048lld:pubmed
pubmed-article:12100152pubmed:authorpubmed-author:SasakiMakotoMlld:pubmed
pubmed-article:12100152pubmed:authorpubmed-author:SugimotoKoich...lld:pubmed
pubmed-article:12100152pubmed:authorpubmed-author:OshimiKazuoKlld:pubmed
pubmed-article:12100152pubmed:authorpubmed-author:TamayoseKenji...lld:pubmed
pubmed-article:12100152pubmed:authorpubmed-author:HayashiKeikoKlld:pubmed
pubmed-article:12100152pubmed:issnTypePrintlld:pubmed
pubmed-article:12100152pubmed:volume118lld:pubmed
pubmed-article:12100152pubmed:ownerNLMlld:pubmed
pubmed-article:12100152pubmed:authorsCompleteYlld:pubmed
pubmed-article:12100152pubmed:pagination229-38lld:pubmed
pubmed-article:12100152pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:meshHeadingpubmed-meshheading:12100152...lld:pubmed
pubmed-article:12100152pubmed:year2002lld:pubmed
pubmed-article:12100152pubmed:articleTitleLow-dose doxorubicin-induced necrosis in Jurkat cells and its acceleration and conversion to apoptosis by antioxidants.lld:pubmed
pubmed-article:12100152pubmed:affiliationDepartment of Haematology, Juntendo University School of Medicine, Tokyo, Japan. ksugimot@med.juntendo.ac.jplld:pubmed
pubmed-article:12100152pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12100152pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12100152lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12100152lld:pubmed